文献速递临床试验与 GCP流行病学与生物统计

CHAPS研究:撒哈拉以南非洲青少年HIV暴露前预防方案的比较—混合方法研究方案(含随机对照试验)

Combined HIV Adolescent Prevention Study (CHAPS): comparison of HIV pre-exposure prophylaxis regimens for adolescents in sub-Saharan Africa-study protocol for a mixed-methods study including a randomised controlled trial.
PubMed 文献 · Trials · 2020-10-30

CHAPS研究采用混合方法,在撒哈拉以南非洲13-24岁人群中开展定性研究识别PrEP使用障碍与促进因素,并开展随机对照试验,利用离体HIV攻击方法比较FTC-TDF与FTC-TAF、不同剂量和给药方案的保护效果,为未来III期PrEP试验选择最佳干预方案提供依据。

要点

  • 研究目的为确定青少年PrEP的最佳药物、剂量和给药方案。
  • 随机试验纳入144名13-24岁未环切HIV阴性男性,随机分入9组。
  • 采用离体HIV攻击切除包皮组织评估不同PrEP方案的保护效果。

核心结论

  • 本研究将提供定性和定量结果,帮助决定未来PrEP III期试验的最佳药物、剂量和方案。
  • 研究还将为撒哈拉以南非洲青少年提供PrEP的成功策略提供关键信息。

研究设计与样本

  • 混合方法研究,在13-24岁年轻人中开展,包括定性研究和随机临床试验(NCT03986970)。
  • 定性研究在南非、乌干达和津巴布韦识别青少年PrEP使用的障碍和促进因素。
  • 随机临床试验招募144名13-24岁HIV阴性未环切男性,来自南非和乌干达两个站点的自愿男性包皮环切门诊,随机分入9组。

关键数值与推荐

  • 一组术前不接受PrEP;其他组接受FTC-TDF或FTC-TAF,用药1或2天,末次给药在术前6或20小时。
  • 对切除的包皮组织进行离体HIV攻击。

临床怎么用

  • 为未来III期PrEP试验选择最佳药物、剂量和方案提供依据。
  • 为撒哈拉以南非洲青少年PrEP实施策略提供关键信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HIV remains a major public health issue, especially in Eastern and Southern Africa. Pre-exposure prophylaxis is highly effective when adhered to, but its effectiveness is limited by cost, user acceptability and uptake. The cost of a non-inferiority phase III trial is likely to be prohibitive, and thus, it is essential to select the best possible drug, dose and schedule in advance. The aim of this study, the Combined HIV Adolescent PrEP and Prevention Study (CHAPS), is to investigate the drug, dose and schedule of pre-exposure prophylaxis (PrEP) required for the protection against HIV and the acceptability of PrEP amongst young people in sub-Saharan Africa, and hence to inform the choice of intervention for future phase III PrEP studies and to improve strategies for PrEP implementation. METHODS: We propose a mixed-methods study amongst young people aged 13-24 years. The first component consists of qualitative research to identify the barriers and motivators towards the uptake of PrEP amongst young people in South Africa, Uganda and Zimbabwe. The second component is a randomised clinical trial (ClinicalTrials.gov NCT03986970, June 2019) using a novel ex vivo HIV challenge method to investigate the optimal PrEP treatment (FTC-TDF vs FTC-TAF), dose and schedule. We will recruit 144 amongst HIV-negative uncircumcised men aged 13-24 years from voluntary male medical circumcision clinics in two sites (South Africa and Uganda) and randomise them into one of nine arms. One group will receive no PrEP prior to surgery; the other arms will receive either FTC-TDF or FTC-TAF, over 1 or 2 days, and with the final dose given either 6 or 20 h prior to surgery. We will conduct an ex vivo HIV challenge on their resected foreskin tissue. DISCUSSION: This study will provide both qualitative and quantitative results to help decide the optimum drug, dose and schedule for a future phase III trial of PrEP. The study will also provide crucial information on successful strategies for providing PrEP to young people in sub-Saharan Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT03986970 . Registered on 14 June 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nash S, Dietrich J, Ssemata AS, et al. Combined HIV Adolescent Prevention Study (CHAPS): comparison of HIV pre-exposure prophylaxis regimens for adolescents in sub-Saharan Africa-study protocol for a mixed-methods study including a randomised controlled trial. Trials. 2020. PMID: 33121503. doi:10.1186/s13063-020-04760-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。